Marked Chart Marked Chart Closed

The Marked Chart Wire · Series of events

Series of events · Obesity Drugs

Obesity drug pipeline and access updates

Recent developments in obesity treatments include new distribution partnerships and clinical trial data from major pharmaceutical companies.

3 eventsNov 6 to Nov 18LLY-2.3%HIMS-6.0%

Updated

The flow in 3 points

  1. Foundayo costs $149 per month through Hims & Hers
  2. Eloralintide phase 2 showed 74% fewer cravings
  3. Zealand Pharma started Phase 2 ZYNERGY study

What happened, in order

Times are Eastern
  1. Where it began

    Access deal

    Eli Lilly and Hims & Hers agreed to sell weight loss medicines via telehealth, with Foundayo at $149 and Zepbound at $299 monthly.

    Read the story
  2. Trial results

    Eli Lilly shared phase 2 data for eloralintide, noting 74% of users had fewer cravings and 52% less food noise.

    Read the story
  3. Latest

    New study

    Zealand Pharma began its Phase 2 ZYNERGY study to test a combination of petrelintide and enicepatide for obesity.

    Read the story

How they connect

The sequence moves from a commercial distribution agreement to new clinical data from Eli Lilly, then to a separate trial launch by Zealand Pharma.

The stocks in this series

  1. LLY-2.3%Eli Lilly$1,351
  2. HIMS-6.0%Hims & Hers Health$16.02

Prices from Based on Thu, Nov 19 close · Opens Fri 9:30 AM ET. Each tile opens the stock's chart and news.

A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.